Laur Birlea, MD
Pain Medicine · Aurora, CONPI 1972778397
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,594 of the $6,164 with a category attached, or 74.5%. AbbVie accounts for 77.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $2,579 and has fallen 90.6% since, to $242 in 2025.
Across 22 payments — averaging $280.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Amgen$565
- Teva Pharmaceuticals USA, Inc.$247
- Biohaven Pharmaceuticals, Inc.$157
- Lundbeck LLC$127
- Novartis$125
- plus $176 from 2 others
Across 6 payments — averaging $8693.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- H. Lundbeck A S$48K
- Teva Pharmaceuticals USA, Inc.$5K
What the payments were for
- Consulting fees$4,59475%
- Food & beverage$1,55525%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $4,768 |
| Amgen | 6 | $565 |
| Teva Pharmaceuticals USA, Inc. | 2 | $247 |
| Biohaven Pharmaceuticals, Inc. | 2 | $157 |
| Lundbeck LLC | 1 | $127 |
| Novartis | 1 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $95 |
| Axsome Therapeutics, Inc. | 1 | $81 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$2,213
- AUSTEDO$149
- AIMOVIG$131
- VYEPTI$127
- NURTEC ODT$124
How this compares
$6,164 in reported general payments places this provider in the 70th percentile of 96 pain medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 114 | $113,506 |
| Nurtec OdtRimegepant Sulfate | 83 | $98,213 |
| UbrelvyUbrogepant | 66 | $62,489 |
| QuliptaAtogepant | 49 | $59,705 |
| Emgality PenGalcanezumab-Gnlm | 59 | $50,135 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 25 | $25,814 |
| ElyxybCelecoxib | 13 | $21,030 |
| Zolmitriptan | 12 | $3,530 |
| Famciclovir | 12 | $2,977 |
| ValacyclovirValacyclovir Hcl | 20 | $1,471 |
| Sumatriptan Succinate | 47 | $1,457 |
| RizatriptanRizatriptan Benzoate | 51 | $1,037 |
| Memantine Hcl | 44 | $930 |
| Pregabalin | 24 | $564 |
| Ondansetron OdtOndansetron | 25 | $538 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $4,768 | $122,194115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 96 pain medicine providers in Colorado.
Other pain medicine in Aurora
- Haley BurkeAurora$55K
- Rachael Rzasa-LynnAurora$6K
- Blake KandahAurora$2K
- Danielle WilhourAurora$2K
- Robert MoghimGolden$273K
- Jack RentzGreenwood Village$264K
- Donald BernardiniEnglewood$102K
- Amar PatelThornton$47K
- David ColumbusLoveland$30K
- Matthew PouliotFort Collins$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.